Allopurinol treatment of renal calcium stone disease

Characterisation of risk factors for stones in hyperuricosuric men attending a stone clinic

Hyperuricosuria is common among stone formers, but its significance is uncertain. To progress our understanding and target treatment, we need to identify and characterise patients with uniform underlying pathology. We aimed to identify hyperuricosuric patients with a primary defect in renal urate reabsorption (renal hyperuricosuria) and to look for associated risk factors for stones. We undertook a retrospective cross-sectional database study of 666 male stone formers attending the Southampton stone clinic. We estimated filtered urate from plasma urate and 24-h creatinine clearance, and the net percentage reabsorbed. 153 men had hyperuricosuria (urine urate >4.80 mmol/24 h); 513 had normouricosuria. Hyperuricosuric men filtered more urate (median 68.1 and 52.5 mmol/24 h) but the ranges overlapped. Thirty hyperuricosuric men with filtered urate below the median for normouricosuria were selected as the renal hyperuricosuria group. Their normal plasma urate and high urate clearance substantiated this classification. In comparison with 60 normouricosuric stone formers matched for filtration, they had a higher incidence of hypercalciuria (67 versus 40%), but similar, high, frequencies of hyperoxaluria (25 and 11%) and phosphaturia (40 and 27%).There were no differences in age at first stone, incidence of stone recurrence or positive family history (20 and 25%). The findings demonstrate multiple risk factors for stones in this subgroup. In comparison, the 30 hyperuricosuric men with the highest filtration had a higher incidence of hyperoxaluria (58%) but fewer (7%) had a positive family history. Creatinine clearance was raised in 73%. An excessive protein intake might be a major correctable factor underlying these abnormalities.

Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria

Two new potential pharmacologic therapies for recurrent stone disease are described. The role of hyperuricosuria in promoting calcium stones is controversial with only some but not all epidemiologic studies demonstrating associations between increasing urinary uric acid excretion and calcium stone disease. The relationship is supported by the ability of uric acid to "salt out" (or reduce the solubility of) calcium oxalate in vitro. A randomized, controlled trial of allopurinol in patients with hyperuricosuria and normocalciuria was also effective in preventing recurrent stones. Febuxostat, a nonpurine inhibitor of xanthine oxidase (also known as xanthine dehydrogenase or xanthine oxidoreductase) may have advantages over allopurinol and is being tested in a similar protocol, with the eventual goal of determining whether urate-lowering therapy prevents recurrent calcium stones. Treatments for cystinuria have advanced little in the past 30 years. Atomic force microscopy has been used recently to demonstrate that effective inhibition of cystine crystal growth is accomplished at low concentrations of l-cystine methyl ester and l-cystine dimethyl ester, structural analogs of cystine that provide steric inhibition of crystal growth. In vitro, l-cystine dimethyl ester had a significant inhibitory effect on crystal growth. The drug's safety and effectiveness will be tested in an Slc3a1 knockout mouse that serves as an animal model of cystinuria.

Relationship of plasma and urine composition to recurrence of calcium urinary stones in patients on drug therapy

Factors relating alterations in plasma and urine composition to recurrence of urinary stones during drug therapy were investigated by using a multiple regression analysis technique. These factors were influenced not only by the efficacy of the drugs but also by other factors (plasma or urinary constituents and overall health of the patients, etc.). In order to study the effect of drug therapy or other treatment on the alteration of plasma and urine constituents, multiple regression analysis is more appropriate than Student's paired t-test which has been used by some workers. These two analytical methods yield different results even if used on the same data.

Does hyperuricosuria play a role in calcium oxalate lithiasis?

This review evaluates the epidemiologic, clinical and experimental evidence for an etiological link between urinary uric acid and the propensity to develop calcium oxalate calculi. While epidemiologic and laboratory studies provide only equivocal support for a synergistic relationship, several clinical trials with allopurinol have demonstrated a reduction in calculus recurrence. These beneficial effects are observed only when allopurinol is given to subjects with calcium oxalate calculi who have isolated hyperuricosuria. The specificity of this effect suggests that there is an important interaction between uric acid and calcium oxalate but the mechanism(s) remain to be elucidated.

Randomized trial of allopurinol in the prevention of calcium oxalate calculi

In a double-blind study, we examined the efficacy of allopurinol in the prevention of recurrent calcium oxalate calculi of the kidney. Sixty patients with hyperuricosuria and normocalciuria who had a history of calculi were randomly assigned to receive either allopurinol (100 mg three times daily) or a placebo. After the study, the placebo group had 63.4 percent fewer calculi (P less than 0.001), whereas the allopurinol group had 81.2 percent fewer calculi (P less than 0.001). During the study period, the mean rate of calculous events was 0.26 per patient per year in the placebo group and 0.12 in the allopurinol group. When the treatment groups were compared by actuarial analysis, the allopurinol group was found to have a significantly longer time before recurrence of calculi (P less than 0.02). We conclude that allopurinol is effective in the prevention of calcium oxalate stones in patients with hyperuricosuria. The large reduction in the frequency of calculi in the placebo group underscores the positive treatment bias that regularly occurs in trials of prophylaxis against renal calculi when historical controls are used.

Medical investigation and treatment of urinary stones: a search for new ideas

The main threads of recent research into the cause and treatment of calcium oxalate/phosphate stones are reviewed. Little progress has been made in recent years, and two main reasons can be identified. First, there has been too much emphasis upon calcium and too little emphasis upon urinary oxalate as causative factors. Second, there has been too much emphasis upon the physical chemistry of simple solutions and too little emphasis upon the study of whole urine.